NCT04238130Completed
Evaluation ctDNA in Patients of Non-Small-Cell Lung Cancer Following Resection
Evaluation Perioperative Dynamic Changes in ctDNA From Patients of Non-Small-Cell Lung Cancer Following Resection for Relapse Prediction
Source: ClinicalTrials.gov · Last updated 6 Dec 2024
Brief summary (registry, in English)
Circulating tumor DNA (ctDNA) is a promising biomarker for noninvasive assessment of cancer burden. In this study, PEAC (Personalized Analysis of Cancer) technology was performed to detect the driver gene mutations from plasma samples and matched tumor tissue samples were detected by NGS platform at baseline. Investigators also applied ctDNA dynamic monitoring using PEAC technology in early stage NSCLC patients with driver mutations positive at baseline, to evaluate the feasibility and their potential clinical application.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 132 (actual)
- First submitted
- 17 Jan 2020
- Start date
- 18 Dec 2019
- Primary completion date
- 1 Nov 2024
- Lead sponsor
- Sun Yat-sen University
- Diseases
- Lung cancer
- NCT number
- NCT04238130
What you commit to
- Study type: Observational
- Participants enrolled: 132
- From 18 Dec 2019 to the primary completion date, 1 Nov 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with other cancers other than NSCLC within five years prior to this study;
Other illness
- Human immunodeficiency virus (HIV) infection;
- NSCLC mixed with patients with small cell lung cancer;
- There is a clear history of neurological or mental disorders, including epilepsy or dementia;
- Conditions that investigators think is not suitable for inclusion.
Other
- Who can not get enough tumor histological specimens (non-cytological) for analysis;
- Pregnant or lactating women;
Who the study is looking for
- Postoperative histopathological diagnosis of TNM stage I to III NSCLC with R0 resection;
- No adjuvant chemotherapy, radiotherapy, targeted drug therapy or biotherapy after surgery;
- Men or women of age ≥18 years and \<75 years old;
- Eastern Cooperative Oncology Group (ECOG) behavior status score 0 to 1.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sun Yat-sen University Cancer Center Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.